Compositions and methods for treating or preventing diseases of body passageways

a technology of body passageways and compositions, applied in the direction of drug compositions, cardiovascular disorders, aerosol delivery, etc., can solve the problems of thrombosis, changes in laminar flow patterns, etc., and achieve the effect of avoiding systemic and unwanted side effects, avoiding urethra instrumentation, and potentially reducing total dosages

Inactive Publication Date: 2005-05-12
ANGIOTECH INT AG (CH) +1
View PDF4 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach allows for effective treatment of various diseases with reduced systemic toxicity, minimized risk of re-blockage, and preservation of tissue integrity, enhancing the long-term outcomes for conditions like vascular diseases and neoplastic obstructions.

Problems solved by technology

For example damage to the endothelium can result in thrombosis, changes to laminar flow patterns, and / or a foreign body reaction to an endoluminal device any of which can initiate the restenosis cascade.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating or preventing diseases of body passageways
  • Compositions and methods for treating or preventing diseases of body passageways
  • Compositions and methods for treating or preventing diseases of body passageways

Examples

Experimental program
Comparison scheme
Effect test

example 1

Manufacture of “Pastes”

[0181] As noted above, the present invention provides a variety of polymeric-containing drug compositions that may be utilized within a variety of clinical situations. For example, compositions may be produced: (1) as a “thermopaste” that is applied to a desired site as a fluid, and hardens to a solid of the desired shape at a specified temperature (e.g., body temperature); (2) as a spray (i.e., “nanospray”) which may delivered to a desired site either directly or through a specialized apparatus (e.g., endoscopy), and which subsequently hardens to a solid which adheres to the tissue to which it is applied; (3) as an adherent, pliable, resilient, drug-loaded-polymer film applied to a desired site either directly or through a specialized apparatus, and which preferably adheres to the site to which it is applied; and (4) as a fluid composed of a suspension of microspheres in an appropriate carrier medium, which is applied to a desired site either directly or via ...

example 2

Manufacture of Microspheres

[0214] Equipment which is preferred for the manufacture of microspheres described below include: 200 ml water jacketed beaker (Kimax or Pyrex), Haake circulating water bath, overhead stirrer and controller with 2 inch diameter (4 blade, propeller type stainless steel stirrer—Fisher brand), 500 ml glass beaker, hot plate / stirrer (Corning brand); 4×50 ml polypropylene centrifuge tubes (Nalgene), glass scintillation vials with plastic insert caps, table top centrifuge (GPR Beckman), high speed centrifuge-floor model (JS 21 Beckman), Mettler analytical balance (AJ 100, 0.1 mg), Mettler digital top loading balance (AE 163, 0.01 mg), automatic pipetter (Gilson). Reagents include Polycaprolactone (“PCL”—mol wt 10,000 to 20,000; Polysciences, Warrington Pa., USA), “washed” (see later method of “washing”) Ethylene Vinyl Acetate (“EVA”), Poly(DL)lactic acid (“PLA”—mol wt 15,000 to 25,000; Polysciences), Polyvinyl Alcohol (“PVA”—mol wt. 124,000 to 186,000; 99% hydro...

example 3

Surfactant Coated Microspheres

A. Materials and Methods

[0223] Microspheres were manufactured from Poly (DL) lactic acid (PLA), poly methylmethacrylate (PMMA), polycaprolactone (PCL) and 50:50 Ethylene vinyl acetate (EVA):PLA essentially as described in Example 2. Size ranged from 10 to 100 um with a mean diameter 45 um.

[0224] Human blood was obtained from healthy volunteers. Neutrophils (white blood cells) were separated from the blood using dextran sedimentation and Ficoll Hypaque centrifugation techniques. Neutrophils were suspended at 5 million cells per ml in Hanks Buffered Salt Solution (“HBSS”).

[0225] Neutrophil activation levels were determined by the generation of reactive oxygen species as determined by chemiluminescence. In particular, chemiluminescence was determined by using an LKB luminometer with 1 uM luminol enhancer. Plasma precoating (or opsonization) of microspheres was performed by suspending 10 mg of microspheres in 0.5 ml of plasma and tumbling at 37° C. for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
pHaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of co-pending U.S. patent application Ser. No. 10 / 671,327, filed Sep. 25, 2003, which is a continuation U.S. patent application Ser. No. 09 / 933,652, filed Aug. 20, 2001, now issued as U.S. Pat. No. 6,759,431, on Jul. 6, 2004; which is a continuation of U.S. patent application Ser. No. 08 / 653,207, filed May 24, 1996, now abandoned, which applications are incorporated herein by reference in their entirety.TECHNICAL FIELD [0002] The present invention relates generally to compositions and methods for treating or preventing diseases of body passageways, and more specifically, to compositions comprising therapeutic agents which may be delivered to the external walls of body passageways. BACKGROUND OF THE INVENTION [0003] There are many passageways within the body which allow the flow of essential materials. These include, for example, arteries and veins, the esophagus, stomach, small and large intestine, bil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61F2/82A61K9/00A61K47/30A61K9/10A61K9/107A61K9/12A61K9/16A61K9/50A61K9/51A61K9/70A61K31/00A61K31/28A61K31/335A61K31/337A61K33/24A61K45/00A61K45/08A61K47/32A61K47/34A61P1/00A61P1/04A61P9/00A61P9/10A61P11/00A61P11/08A61P13/00A61P13/02A61P13/08A61P15/00A61P27/02A61P31/04A61P31/06A61P35/00A61P43/00
CPCA61K9/0024A61K47/34A61K9/1075A61K9/12A61K9/1635A61K9/1647A61K9/1652A61K9/167A61K9/5031A61K9/5138A61K9/5146A61K9/5153A61K9/5192A61K9/70A61K9/7007A61K31/00A61K31/28A61K31/335A61K31/337A61K33/24A61K9/10A61P1/00A61P1/04A61P11/00A61P11/08A61P13/00A61P13/02A61P13/08A61P15/00A61P27/02A61P31/04A61P31/06A61P35/00A61P43/00A61P9/00A61P9/10
InventorHUNTER, WILLIAM L.MACHAN, LINDSAY S.
OwnerANGIOTECH INT AG (CH)